HK1245100A1 - 作為fxr/tgr5激動劑的膽汁酸類似物及其使用方法 - Google Patents
作為fxr/tgr5激動劑的膽汁酸類似物及其使用方法Info
- Publication number
- HK1245100A1 HK1245100A1 HK18104548.9A HK18104548A HK1245100A1 HK 1245100 A1 HK1245100 A1 HK 1245100A1 HK 18104548 A HK18104548 A HK 18104548A HK 1245100 A1 HK1245100 A1 HK 1245100A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fxr
- methods
- bile acid
- acid analogs
- tgr5 agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562114773P | 2015-02-11 | 2015-02-11 | |
PCT/US2016/017554 WO2016130809A1 (en) | 2015-02-11 | 2016-02-11 | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1245100A1 true HK1245100A1 (zh) | 2018-08-24 |
Family
ID=56565728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104548.9A HK1245100A1 (zh) | 2015-02-11 | 2018-04-06 | 作為fxr/tgr5激動劑的膽汁酸類似物及其使用方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10246483B2 (zh) |
EP (1) | EP3256134A4 (zh) |
JP (1) | JP2018505190A (zh) |
KR (1) | KR20170133339A (zh) |
CN (1) | CN107249594A (zh) |
AU (1) | AU2016219266A1 (zh) |
BR (1) | BR112017017238A2 (zh) |
CA (1) | CA2975257A1 (zh) |
HK (1) | HK1245100A1 (zh) |
MX (1) | MX2017010376A (zh) |
PH (1) | PH12017501339A1 (zh) |
RU (1) | RU2017130466A (zh) |
SG (1) | SG11201706089RA (zh) |
WO (1) | WO2016130809A1 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2017118569A (ru) | 2014-11-06 | 2018-12-06 | Энанта Фармасьютикалс, Инк. | Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
CA2968404A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
JP6785788B2 (ja) | 2015-03-31 | 2020-11-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | Fxr/tgr5アゴニストとしての胆汁酸誘導体およびその使用方法 |
US10517321B2 (en) | 2015-07-10 | 2019-12-31 | Sweet Green Fields USA LLC | Compositions of steviol multiglycosylated derivatives and stevia components |
WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
CN106237332A (zh) * | 2016-08-11 | 2016-12-21 | 河南大学 | 核受体fxr在肝癌干细胞靶向治疗中的应用 |
JP7057783B2 (ja) | 2016-11-29 | 2022-04-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | スルホニル尿素胆汁酸誘導体の調製方法 |
US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
US10676500B2 (en) | 2017-04-07 | 2020-06-09 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
JP7224307B2 (ja) | 2017-06-23 | 2023-02-17 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 胆汁酸誘導体の調製のための方法及び中間体 |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | D型肝炎ウイルスによる感染を処置するためのfxrアゴニストの使用 |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
WO2022152770A1 (en) | 2021-01-14 | 2022-07-21 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
EP4329761A1 (en) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1592791A (en) | 1977-01-07 | 1981-07-08 | Radiochemical Centre Ltd | Selenium- or tellurium-containing bile acids and derivatives thereof |
WO1987002367A2 (en) | 1985-10-18 | 1987-04-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
IT1255485B (it) | 1992-08-04 | 1995-11-06 | Erregierre Ind Chim | Processo per preparare gli acidi biliari coniugati con la glicina e relative composizioni terapeutiche per il trattamento dell'insufficienza epatica |
TW289020B (zh) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
TW289757B (zh) * | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
US5646316A (en) | 1994-04-08 | 1997-07-08 | Osteoarthritis Sciences, Inc. | Bile acid inhibitors of metalloproteinase enzymes |
JPH1160594A (ja) * | 1997-08-25 | 1999-03-02 | Sankyo Co Ltd | 胆汁酸誘導体 |
JP3865890B2 (ja) | 1997-09-30 | 2007-01-10 | 富士フイルムホールディングス株式会社 | ポジ型感光性組成物 |
US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
US20020098999A1 (en) | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
ITMI20021080A1 (it) | 2002-05-21 | 2003-11-21 | Marcello Izzo | Associazioni farmaceutiche per uso topico a base di chelati del ferroinibitori delle metalloproteasi e fattore xiii per il trattamento dell |
EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
JP5094384B2 (ja) * | 2004-03-12 | 2012-12-12 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Fxrリガンドを使用する線維症の処置 |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
CA2642220A1 (en) | 2006-02-14 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
WO2007111994A2 (en) | 2006-03-22 | 2007-10-04 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with er stress |
JP5222846B2 (ja) | 2006-06-27 | 2013-06-26 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Fxr媒介疾患または状態の予防または治療のためのfxrリガンドとしての胆汁酸誘導体 |
EP2044100A2 (en) | 2006-07-17 | 2009-04-08 | Novartis AG | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
ES2438271T3 (es) | 2007-01-19 | 2014-01-16 | Intercept Pharmaceuticals, Inc. | Ácidos biliares 23-sustituidos como moduladores de TGR5 y métodos de uso de los mismos |
EP1947108A1 (en) * | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
CA2697744C (en) | 2007-09-06 | 2016-06-14 | Genaera Corporation | A method for treating diabetes |
US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
US20130034536A1 (en) | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis |
US11154559B2 (en) | 2011-09-29 | 2021-10-26 | Ethicon Endo-Surgery, Inc. | Methods and compositions of bile acids |
BR112014027204A2 (pt) | 2012-05-01 | 2017-06-27 | Catabasis Pharmaceuticals Inc | conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos |
US9238673B2 (en) | 2012-06-19 | 2016-01-19 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
WO2014036379A2 (en) | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140206657A1 (en) | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
BR112015028399B1 (pt) | 2013-05-14 | 2021-11-16 | Intercept Pharmaceuticals, Inc | Derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x, composição farmacêutica e uso dos referidos derivados |
BR112016002268B1 (pt) | 2013-08-01 | 2022-11-01 | The Penn State Research Foundation | Uso de inibidores do receptor x farnesoide |
US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
LT3149019T (lt) | 2014-05-29 | 2020-02-25 | Bar Pharmaceuticals S.R.L. | Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai |
RU2017118569A (ru) | 2014-11-06 | 2018-12-06 | Энанта Фармасьютикалс, Инк. | Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения |
US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
CA2968404A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
WO2016173493A1 (en) | 2015-04-28 | 2016-11-03 | Shanghai De Novo Pharmatech Co. Ltd. | Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof |
EP3290429A1 (en) | 2015-04-28 | 2018-03-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Cholic acid derivative, and preparation method and medical use thereof |
CN107531743B (zh) | 2015-04-29 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 鹅去氧胆酸衍生物 |
JP6861703B2 (ja) | 2015-06-19 | 2021-04-21 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5修飾物質およびその使用方法 |
US10604544B2 (en) | 2015-08-07 | 2020-03-31 | Intercept Pharmaceuticals, Inc. | Methods for preparation of bile acids and derivatives thereof |
CN105175473B (zh) | 2015-08-19 | 2018-12-21 | 丽珠医药集团股份有限公司 | 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途 |
CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
WO2017053826A1 (en) | 2015-09-24 | 2017-03-30 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation bile acid derivatives |
IL258359B2 (en) | 2015-10-07 | 2023-11-01 | Intercept Pharmaceuticals Inc | Paranoid X receptor modulators. |
KR20180100703A (ko) | 2016-01-28 | 2018-09-11 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 스테로이드 유도체 fxr 작용체 |
WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
SI3426348T1 (sl) | 2016-03-11 | 2021-11-30 | Intercept Pharmaceuticals, Inc. | Derivat 3-dezoksi in njegovi farmacevtski sestavki |
US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
-
2016
- 2016-02-11 KR KR1020177025456A patent/KR20170133339A/ko unknown
- 2016-02-11 CN CN201680010001.1A patent/CN107249594A/zh active Pending
- 2016-02-11 EP EP16749885.6A patent/EP3256134A4/en not_active Withdrawn
- 2016-02-11 BR BR112017017238A patent/BR112017017238A2/pt not_active Application Discontinuation
- 2016-02-11 SG SG11201706089RA patent/SG11201706089RA/en unknown
- 2016-02-11 US US15/041,811 patent/US10246483B2/en active Active
- 2016-02-11 WO PCT/US2016/017554 patent/WO2016130809A1/en active Application Filing
- 2016-02-11 JP JP2017541843A patent/JP2018505190A/ja active Pending
- 2016-02-11 AU AU2016219266A patent/AU2016219266A1/en not_active Abandoned
- 2016-02-11 RU RU2017130466A patent/RU2017130466A/ru unknown
- 2016-02-11 MX MX2017010376A patent/MX2017010376A/es unknown
- 2016-02-11 CA CA2975257A patent/CA2975257A1/en not_active Abandoned
-
2017
- 2017-07-25 PH PH12017501339A patent/PH12017501339A1/en unknown
-
2018
- 2018-04-06 HK HK18104548.9A patent/HK1245100A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US10246483B2 (en) | 2019-04-02 |
MX2017010376A (es) | 2017-12-20 |
RU2017130466A (ru) | 2019-03-12 |
WO2016130809A1 (en) | 2016-08-18 |
US20160229886A1 (en) | 2016-08-11 |
CN107249594A (zh) | 2017-10-13 |
CA2975257A1 (en) | 2016-08-18 |
PH12017501339A1 (en) | 2017-12-18 |
BR112017017238A2 (pt) | 2018-04-10 |
EP3256134A4 (en) | 2018-10-03 |
JP2018505190A (ja) | 2018-02-22 |
EP3256134A1 (en) | 2017-12-20 |
KR20170133339A (ko) | 2017-12-05 |
SG11201706089RA (en) | 2017-09-28 |
AU2016219266A1 (en) | 2017-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245100A1 (zh) | 作為fxr/tgr5激動劑的膽汁酸類似物及其使用方法 | |
HK1244708A1 (zh) | 作爲fxr/tgr5激動劑的胆汁酸類似物及其使用方法 | |
ZA202102769B (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
HK1243930A1 (zh) | 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法 | |
ZA201908293B (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
IL265803A (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
IL247529B (en) | Preparations of choline ester lipoic acid and methods of use | |
HK1246690A1 (zh) | 用於鑒定高度特異性核酸酶的方法和組合物 | |
SG10201709955PA (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
GB2561121B (en) | Branched acid emulsifier compositions and methods of use | |
GB201408738D0 (en) | Components and methods for formulation of components |